about
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor CediranibA reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencingSCN10A Mutation in a Patient with Erythromelalgia Enhances C-Fiber Activity Dependent Slowing.The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.Defining actionable mutations for oncology therapeutic development.EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice.A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers.Exonic mutations in SCN9A (NaV1.7) are found in a minority of patients with erythromelalgiaCirculating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I TrialOptimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA
P50
Q27315803-5E4CB931-E6F0-47FC-A533-FEC877A6A054Q35336961-96D82758-11F7-41BD-805D-D760FEDFB1B0Q36123895-BECD1DEF-D1E0-43A3-B98D-95E3B5946C84Q36316643-B1DA626E-D29D-4DF0-8C4D-788E9AB605EEQ38816901-9262F540-A699-44F9-84E1-5F2035FE5546Q40324544-C436F77D-877F-4ED9-8DC1-33382268073FQ47351280-21E90C8D-5710-4EFA-96BF-4DADDE7AB8E3Q50078519-42C01F9F-373E-48DF-9153-84260C3122C3Q89133687-BD4AEEAC-0685-45A6-AE5F-89A49B7552F1Q90785702-1B8D5565-4EA1-4580-BB79-FC1CA58013B5Q93064238-E81F7E98-1F79-4D13-AD73-7E1784A69F22
P50
description
investigador
@es
researcher
@en
name
T Hedley Carr
@en
type
label
T Hedley Carr
@en
prefLabel
T Hedley Carr
@en
P31
P496
0000-0002-8147-9855